Pressemitteilung -
Ursatec GmbH, Förde Ventures GmbH and SolyPlus GmbH have signed a letter of intent based on SolyPlus’ pioneering technology for the optimal utilization of biopolymers as nasal, throat and skin sprays.
Ursatec GmbH, Förde Ventures GmbH and SolyPlus GmbH have signed a letter of intent
based on SolyPlus’ pioneering technology for the optimal utilization of biopolymers as nasal, throat and skin sprays.
SolyPlus, a biotech company based in Haselund, Schleswig-Holstein, has already launched chitosan-containing chewing gum and candies with other licensees as dietary supplements in 2021.
In order to use the strong antiviral and antibacterial effect of vegan chitosan for comprehensive oral hygiene and as additional protection against infections (also against covid, influenza, etc.), Ursatec from Tholey, Saarland, the market leader of dosing systems for preservative-free application and a product development expert, as well as Förde Ventures from Meyn, Schleswig-Holstein, as financier could be won of the pre-clinical and clinical development of such medtech products.
In addition to the corresponding patent protection, SolyPlus supplies the recipe for the chitosan-hyaluronic acid combination, Ursatec carries out the development, production and approval of the medical devices, while Förde Ventures bears the majority of the development costs. The marketing should take place via appropriate medtech companies, both in the human and veterinary area (animal hygiene).
"This is an important step for SolyPlus to have found specialized and local partners to develop, produce, approve and market the innovative chitosan-containing sprays worldwide," says Dr. Joe Bender, Managing Director of SolyPlus.
"And Ursatec secures the production of several patent-protected and future-oriented products that can make a real contribution to public health," comments Dr. Andreas Bilstein, Managing Director of Ursatec. Mr. Volker Haak, Managing Director of Förde Ventures adds, "that this investment will support the product development of human-relevant medical devices and that we can make an important contribution to keeping society healthy.”
Further information on the three partners can be found at:
https://www.ursatec.com/ & https://foerde-ventures.de/ & SolyPlus
Links
Themen
- Gesundheit, Gesundheitswesen, Pharmazeutik
SolyPlus GmbH, founded in Berlin in 2017, is a start-up biotechnology company based in Haselund, Nordfriesland, since 2020.
SolyPlus technology makes it possible to improve numerous products and develop new ones forcosmetics, pharmaceuticals and medtech use. We are a team of experienced experts dedicated to developing new sustainable products to overcome unmet medical needs for a healthier future.
We transform naturally occurring biopolymers into a new format ("smart materials") so that their full potential can be harnessed for highly innovative medical devices and cosmetic applications. Our products are not only sustainable and environmentally friendly, but also help to overcome unmet medical needs. In the meantime, we have already launched five products in the cosmetics and food sectors.
